Abstract:Natural, extracellular membrane vesicles secreted by Gram-negative bacteria, outer membrane vesicles (OMVs), contain numerous pathogen-associated molecular patterns which can activate systemic immune responses. Previous studies have shown that OMVs induce strong IFN-γ- and T cell-mediated anti-tumor effects in mice. However, IFN-γ is known to upregulate immunosuppressive factors in the tumor microenvironment, especially the immune checkpoint programmed death 1 ligand 1 (PD-L1), which may hamper T cell function and limit immunotherapeutic effectiveness. Here, we report the development of genetically engineered OMVs whose surface has been modified by insertion of the ectodomain of programmed death 1 (PD1). This genetic modification does not affect the ability of OMVs to trigger immune activation. More importantly, the engineered OMV-PD1 can bind to PD-L1 on the tumor cell surface and facilitate its internalization and reduction, thereby protecting T cells from the PD1/PD-L1 immune inhibitory axis. Through the combined effects of immune activation and checkpoint suppression, the engineered OMVs drive the accumulation of effector T cells in the tumor, which, in turn, leads to a greater impairment of tumor growth, compared with not only native OMVs but also the commonly used PD-L1 antibody. In conclusion, this work demonstrates the potential of bioengineered OMVs as effective immunotherapeutic agents that can comprehensively regulate the tumor immune microenvironment to effect markedly increased anti-tumor efficacy.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acsnano.0c03776?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acsnano.0c03776</a>.Additional figures for further characterization of OMVs and OMV-PD1 (Supplementary Figure 1); BMDCs mature, TLRs response, and CD49b+ NK cells quantification (Supplementary Figures 2, 3, and 4); PD-L1 upregulation in tumor cells in response to OMVs or IFN-γ (Supplementary Figure 5); immunoprecipitation results with OMVs and OMV-PD1 (Supplementary Figure 6); cell-binding and uptake studies (Supplementary Figures 7 and 8); intracellular fate of OMVs and OMV-PD1 (Supplementary Figure 9); proportion of proliferative T cells (Supplementary Figure 10); OMV-PD1 blood retention time (Supplementary Figure 11); cytotoxicity on B16, CT26, and HUVEC (Supplementary Figure 12); B16 and CT26 tumor images and average body weight (Supplementary Figure 13); analysis of effector memory T cells (CD3+CD8+CD44+CD62L–), CD49b+ cells, and CD11b+ cells (Supplementarys Figure 14 and 15); quantification analysis of PDL1 (Supplementary Figure 16); percentage of IFN-γ+CD8+ T cells (Supplementary Figure 17); biosafety of OMVs (Supplementary Figures 18 and 19); effects of immunotherapy on organ histology (Supplementary Figure 20); and Pearson's colocalization coefficiencts (PCC) of PD-L1 and acid compartments (Supplementary Table 1) (<a class="ext-link" href="/doi/suppl/10.1021/acsnano.0c03776/suppl_file/nn0c03776_si_001.pdf">PDF</a>)This article has not yet been cited by other publications.

Extracellular vesicle-packaged PD-L1 impedes macrophage-mediated antibacterial immunity in preexisting malignancy

Extracellular vesicle PD-L1 in reshaping tumor immune microenvironment: biological function and potential therapy strategies

PD-L1+ Exosomes from Bone Marrow-Derived Cells of Tumor-Bearing Mice Inhibit Antitumor Immunity

PD-L1+ macrophages suppress T cell-mediated anticancer immunity

Colorectal Cancer‐Derived Small Extracellular Vesicles Promote Tumor Immune Evasion by Upregulating PD‐L1 Expression in Tumor‐Associated Macrophages

Macrophages facilitate tumor cell PD‐L1 expression via an IL‐1β‐centered loop to attenuate immune checkpoint blockade

Tumor-associated macrophage enhances PD-L1-mediated immune escape of bladder cancer through PKM2 dimer-STAT3 complex nuclear translocation

PD-L1 expression by dendritic cells is a key regulator of T-cell immunity in cancer

Colorectal Cancer‐Derived Small Extracellular Vesicles Promote Tumor Immune Evasion by Upregulating PD‐L1 Expression in Tumor‐Associated Macrophages (adv. Sci. 9/2022)

M2 macrophages promote PD-L1 expression in triple-negative breast cancer via secreting CXCL1

Tumor-derived small extracellular vesicles promote breast cancer progression by upregulating PD-L1 expression in macrophages

Engineered T cell extracellular vesicles displaying PD-1 boost anti-tumor immunity

IFNα-induced BST2+ Tumor-Associated Macrophages Facilitate Immunosuppression and Tumor Growth in Pancreatic Cancer by ERK-CXCL7 Signaling

Bacterial Outer Membrane Vesicles Presenting Programmed Death 1 for Improved Cancer Immunotherapy via Immune Activation and Checkpoint Inhibition

Tumor-derived microparticles promote the progression of triple-negative breast cancer via PD-L1-associated immune suppression

Siglec-15 on macrophages suppress the immune microenvironment in patients with PD-L1 negative non-metastasis lung adenocarcinoma

Tumor-associated macrophages promote PD-L1 expression in tumor cells by regulating PKM2 nuclear translocation in pancreatic ductal adenocarcinoma

PD-1 Shapes B Cells as Evildoers in the Tumor Microenvironment.

Tumor-derived exosomes antagonize innate antiviral immunity

Mechanisms underlying low-clinical responses to PD-1/PD-L1 blocking antibodies in immunotherapy of cancer: a key role of exosomal PD-L1

Targeting tumor-associated macrophage-derived CD74 improves efficacy of neoadjuvant chemotherapy in combination with PD-1 blockade for cervical cancer